Cutaneous Melanoma ARTISTRY-6, Cohorts 3 & 4
Phase 2

Dosing: Nemvaleukin (LFIV) Monotherapy and Combination with Pembrolizumab Anticipated Program Milestone:  Preliminary data readout for cohort 3 (monotherapy) expected in 1H2025 and for cohort 4 (combination therapy) in 2H 2025 (subject to patient enrollment) >> Learn more about Nemvaleukin Alfa >> Visit the ARTISTRY-6 study website

Read More

Platinum-Resistant Ovarian Cancer ARTISTRY-7
Phase 3

Dosing: Nemvaleukin (IV) Monotherapy and Combination with Pembrolizumab (Potentially Registrational) Anticipated Program Milestone:  Interim readout expected in Q1 2025, with final OS projected in 1H 2026 (subject to event accrual) >> Learn more about Nemvaleukin Alfa >> Visit the ARTISTRY-7 study website

Read More